Piper Sandler upgraded Xencor (XNCR) to Overweight from Neutral with a price target of $30, up from $20. Xencor is expanding its XmAb technology into autoimmune disease and will report initial Phase I healthy volunteer data on XmAb942 in the first half of 2025, the analyst tells investors in a research note. The firm tells investors to own the shares into the 2025 data.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio